Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154017 | 0.89 | MAPT (0.65) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL5559730 | 0.83 | GAA (0.59) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL4775809 | 0.82 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL16106421 | 0.81 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5448142 | 0.80 | MAPT (1.00) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL3042603 | 0.80 | ALDH1A1 (0.54) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL4574907 | 0.80 | EPHX1 (0.57) | MAPTALDH1A1SMN1; SMN2EPHX1KMT2A | |
| SCHEMBL11163790 | 0.79 | ALDH1A1 (0.57) | MAPTALDH1A1SMN1; SMN2EPHX1NPC1 | |
| SCHEMBL3053533 | 0.79 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5038529 | 0.78 | MAPT (0.56) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-29 | — | — | US | disclosed |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-08 | — | — | US | disclosed |
| US-7368446-B2 | adenosine receptor antagonist; neuroprotectant, antidepressant, anxiolitic, antihypoxic agent; antiischemic and anticonvulsant; Alzheimer's, Parkinson's, Huntington's diseases, schizophrenia, pain, respiration deficits, attention deficit hyper-activity disorder (ADHA), drug addiction | HOFFMANN-LA ROCHE INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368446-B2 | adenosine receptor antagonist; neuroprotectant, antidepressant, anxiolitic, antihypoxic agent; antiischemic and anticonvulsant; Alzheimer's, Parkinson's, Huntington's diseases, schizophrenia, pain, respiration deficits, attention deficit hyper-activity disorder (ADHA), drug addiction | HOFFMANN-LA ROCHE INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368446-B2 | adenosine receptor antagonist; neuroprotectant, antidepressant, anxiolitic, antihypoxic agent; antiischemic and anticonvulsant; Alzheimer's, Parkinson's, Huntington's diseases, schizophrenia, pain, respiration deficits, attention deficit hyper-activity disorder (ADHA), drug addiction | HOFFMANN-LA ROCHE INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1303272-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1753760-B1 | 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL)-AMIDE | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| EP-1753760-B1 | 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL)-AMIDE | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| WO-2004060879-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-07-15 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| WO-2003045386-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | MAPT 3145/4885ALDH1A1 383/4885SMN1; SMN2 3173/4885 |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | MAPT 3067/4885ALDH1A1 473/4885SMN1; SMN2 3476/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | MAPT 3145/4885ALDH1A1 383/4885SMN1; SMN2 3173/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | MAPT 3145/4885ALDH1A1 383/4885SMN1; SMN2 3173/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | MAPT 3067/4885ALDH1A1 473/4885SMN1; SMN2 3476/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | MAPT 3145/4885ALDH1A1 383/4885SMN1; SMN2 3173/4885 |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | CBR3, CBR1, OXTR | MAPT 4736/4885ALDH1A1 2709/4885SMN1; SMN2 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.